Last reviewed · How we verify
XBI-302
At a glance
| Generic name | XBI-302 |
|---|---|
| Sponsor | Shenzhen Xbiome Biotech Co., Ltd. |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Safety and Tolerability of FMT Capsules in Healthy Volunteers (PHASE1)
- Study of FMT Combined With Nivolumab in Gastric Cancer (NA)
- Fecal Microbiota Transplant (FMT) Capsule for Improving the Efficacy of GI-aGVHD (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- XBI-302 CI brief — competitive landscape report
- XBI-302 updates RSS · CI watch RSS
- Shenzhen Xbiome Biotech Co., Ltd. portfolio CI